Advertisement

Related Videos

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Opening Session Panel Discussion

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Welcome and Introduction to Vi3C

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Advertisement

Advertisement




Jul
27
Today In Oncology
Cancer Survivors and Providers Differ on Cannabis Risk Awareness and Communication
Paraneoplastic Neurological Syndromes Associated With Improved Survival in SCLC
POLARGO Trial Shows Survival Benefit With Polatuzumab Vedotin–Based Regimen in Relapsed or Refractory DLBCL
FDA Approves Zidesamtinib for Second-Line Treatment of ROS1-Positive NSCLC
AI-Derived Bone Marrow Architecture Score Improves Disease Assessment in Myelodysplastic Neoplasms
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo